title: Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications.
abstract: BACKGROUND
  Intraductal papillary mucinous neoplasms (IPMNs) are increasingly recognized entities, whose management remains sometimes controversial, due to the high rate of benign lesions and on the other side to the good survival after resection of malignant ones.
  
  
  METHODS
  Retrospective analysis of a prospectively collected Western series of IPMN.
  
  
  RESULTS
  Forty cases of IPMN were analysed (1992-2007). Most patients were symptomatic (72.5%); cholangio-MRI had the best diagnostic accuracy both for the tumour nature (83.3%) and for the presence of malignancy (57.1%). ERCP was done in 8 cases (20%), and the results were poor. Thirteen patients were treated by pancreatic resection and 27 were maintained in follow-up. Total pancreatectomy was performed in 46% of the cases; in situ and invasive carcinoma were recognized in 15.4% and 38.4% of the cases, respectively. The mean follow-up was 42 months (range 12-72). One only patients with nodal metastases died 16 months after the operation for disease progression, while 91.6% of the operated patients are disease free. Out of the 27 not resected patients, 2 out of 4 presenting a lesion at high risk for malignancy died, while the remaining are in good conditions and disease free, with a mean follow-up of 31 months.
  
  
  CONCLUSIONS
  Therapeutic indication for IPMNs is mainly based upon radiological evaluation of the risk of malignancy. While the main duct tumours should be resected, preserving whenever possible a portion of the gland, the secondary ducts tumours may be maintained under observation, in absence of radiological elements of suspicion such as size larger than 3 cm, or a wall greater than 3 mm or nodules or papillae in the context of the cyst.
authors.affiliation: Department of Medical and Surgical Sciences, Surgical Clinic, Brescia University, P,le Spedali Civili, 1, 25123 Brescia, Italy. baiocchi@med.unibs.it
authors.forename: Gian Luca
authors.initials: GL
authors.lastname: Baiocchi
authors.forename: Nazario
authors.initials: N
authors.lastname: Portolani
authors.forename: Guido
authors.initials: G
authors.lastname: Missale
authors.forename: Carla
authors.initials: C
authors.lastname: Baronchelli
authors.forename: Federico
authors.initials: F
authors.lastname: Gheza
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Cantù
authors.forename: Luigi
authors.initials: L
authors.lastname: Grazioli
authors.forename: Stefano M
authors.initials: SM
authors.lastname: Giulini
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D021441:Carcinoma, Pancreatic Ductal / Q000473:pathology* / Q000601:surgery; D002291:Carcinoma, Papillary / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000601:surgery; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome